Loading...
Market
What will be the percentage increase in Vyvanse sales in Q4 2024 compared to Q4 2023?
2
Resolution / Starting Odds
0-10% • 25%
11-20% • 25%
21-30% • 25%
31% or more • 25%
Takeda Pharmaceutical's official financial reports
Story
DEA Increases Vyvanse Production Limit by 24% to Address ADHD Drug Shortage
Sep 4, 2024, 11:15 AM
The U.S. Drug Enforcement Administration (DEA) has increased the production limit for Takeda Pharmaceutical's ADHD drug Vyvanse and its generic versions by about 24% to address the ongoing shortage of the medication in the United States. This decision aims to mitigate the impact of the current drug shortage affecting ADHD treatment. The US is allowing 24% more production of Vyvanse and its generic rivals to address treatment shortages.
View original story
Similar markets
Yes • 50%
No • 50%
Increase by more than 5% • 25%
Increase by 0-5% • 25%
Decrease by 0-5% • 25%
Decrease by more than 5% • 25%
More than 20% increase • 25%
10%-20% increase • 25%
0%-10% increase • 25%
Decrease • 25%
Less than 20% • 25%
20% to 30% • 25%
30% to 40% • 25%
More than 40% • 25%
Increase by more than 10% • 25%
Increase by 0-10% • 25%
Decrease by 0-10% • 25%
Decrease by more than 10% • 25%
Less than 3% • 25%
3% to 4% • 25%
4% to 5% • 25%
More than 5% • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
10-15% • 25%
0-5% • 25%
5-10% • 25%
15% or more • 25%
Less than $1 billion • 25%
$1 billion - $1.5 billion • 25%
$1.5 billion - $2 billion • 25%
More than $2 billion • 25%
0-10% • 25%
11-20% • 25%
21-30% • 25%
Above 30% • 25%
0-10% • 25%
10-20% • 25%
20-30% • 25%
30% or more • 25%